免疫治疗对泌尿生殖系统恶性肿瘤局部治疗的影响
本文系统综述了2011至2018年间PubMed与ClinicalTrials.gov上关于免疫治疗在泌尿生殖系统恶性肿瘤局部治疗中应用的文献,共纳入24篇出版物。早期前瞻性试验提示,尿路上皮癌新辅助免疫治疗后病理完全缓解率较高,阿替利珠单抗组为29%,帕博利珠单抗组为39.5%。作者认为现有证据有限,但初步结果令人鼓舞,多项前瞻性试验正在进行中。
要点
- 尿路上皮癌新辅助免疫治疗后病理完全缓解率:阿替利珠单抗29%,帕博利珠单抗39.5%
- 膀胱癌、肾癌和前列腺癌的手术前后多项新辅助及辅助免疫治疗试验正在进行中
- 转移性疾病中,影像学反应极佳的特定患者可在免疫治疗后讨论延迟局部治疗
核心结论
- 关于免疫治疗对泌尿生殖系统恶性肿瘤局部治疗肿瘤学影响的证据很少,但初步结果令人鼓舞,且许多前瞻性试验正在进行中。
研究设计与样本
- 按照PRISMA声明对PubMed和ClinicalTrials.gov进行批判性综述,纳入2011年至2018年的前瞻性和回顾性研究,最终纳入24篇出版物,其中尿路上皮癌10篇、肾细胞癌7篇、前列腺癌6篇、生殖细胞癌1篇。
主要发现
- 尿路上皮癌新辅助免疫治疗后病理完全缓解率:阿替利珠单抗组为29%,帕博利珠单抗组为39.5%。
- 膀胱癌、肾癌和前列腺癌的手术前后多项新辅助及辅助试验仍在进行中。
- 免疫治疗与放疗的联合正在探索中,可能为根治性治疗提供一种有趣的策略。
- 在转移性疾病中,影像学反应极佳的特定患者可在免疫治疗后讨论延迟局部治疗。
关键数值与推荐
- 尿路上皮癌新辅助免疫治疗后病理完全缓解率:阿替利珠单抗组29%,帕博利珠单抗组39.5%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 关于免疫治疗对泌尿生殖系统恶性肿瘤局部治疗肿瘤学影响的证据很少。
- 原文未报告其他局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Management of metastatic genitourinary malignancies has recently been transformed through the use of immune checkpoint inhibitors. The best way to integrate them into local treatment paradigms is still under investigation. OBJECTIVE: To systematically evaluate evidence regarding the use of immunotherapy in the treatment of local disease, in both the perioperative and the metastatic setting. EVIDENCE ACQUISITION: We performed a critical review of PubMed and ClinicalTrials.gov according to the Preferred Reporting Items for Systematic Review and Meta-analyses (PRISMA) statement. Prospective and retrospective studies between 2011 and 2018 were included. Twenty-four publications were selected for inclusion, including 10 on urothelial carcinoma, seven on renal cell carcinoma, six on prostate cancer, and one on germ-cell cancer. EVIDENCE SYNTHESIS: Prospective early-phase trials investigating neoadjuvant immunotherapy prior to cystectomy in urothelial carcinoma suggest a high rate of pathological complete response, from 29% with atezolizumab to 39.5% with pembrolizumab. Several neoadjuvant and adjuvant trials are still ongoing in bladder, renal, and prostate cancers, before or after surgery. The combination of immunotherapy and radiotherapy is being explored and could offer an interesting strategy for definitive treatment modality with curative intent. Finally, in metastatic disease, delayed local treatment could be discussed after immunotherapy in selected patients with an excellent radiographic response. CONCLUSIONS: Little evidence exists on the oncological impact of immunotherapy on the local treatment of genitourinary malignancies, but preliminary results are encouraging and many prospective trials are ongoing. PATIENT SUMMARY: In this study, we review recent advances in immunotherapy and its role in local treatment. Immunotherapy is evaluated before or after surgery, or in combination with radiotherapy for localized disease. Ongoing trials will bring clarity on the local downstaging effect of immunotherapy and its association with oncological and functional outcomes.
引用
- Pignot G, Loriot Y, Kamat AM, et al. Effect of Immunotherapy on Local Treatment of Genitourinary Malignancies. Eur Urol Oncol. 2019. PMID: 31277773. doi:10.1016/j.euo.2019.01.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。